Web28 Jun 2024 · SNDX-5613 is a potent, selective, small molecule inhibitor of the menin-MLL binding interaction that is being developed for the treatment of mixed lineage leukemia rearranged (MLLr) acute ... Web29 Apr 2024 · About SNDX-5613. SNDX-5613 is a potent, selective, small molecule inhibitor of the menin-MLL binding interaction that is being developed for the treatment of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) and NPM1 mutant AML. In preclinical models of MLL-r …
SNDX (シンダックス・ファーマシューティカルズ) 株価・配 …
Web15 Nov 2024 · SNDX-5613 (revumenib) is a potent, selective inhibitor of the menin-KMT2A interaction. In this first-in-human Ph 1 trial, we present the updated safety, pharmacokinetics, pharmacodynamics and efficacy of monotherapy with SNDX-5613 in pts with relapsed or refractory (R/R) acute leukemia, including those with KMT2Ar or mNPM1 (AUGMENT-101). Web26 Mar 2024 · 米国株投資の参考となるシンダックス・ファーマシューティカルズ(Syndax Pharmaceuticals, Inc.:SNDX)の決算・業績・参考サイト ... open source video editing programs
Syndax Pharmaceuticals Announces Preclinical Profile and Initial …
Web1 May 2024 · Preclinical and initial clinical data for SNDX-5613 have been presented at the 2024 American Association for Cancer Research (AACR) Virtual Annual Meeting I by Jerry McGeehan. 2 Preclinical data 2 In eight MLL-r patient derived xenograft (PDX) models, the SNDX-50469 menin inhibitor demonstrated single-agent activity with marked survival … WebSyndax Pharmaceuticals, Incのライブチャートで株式のプライスアクションを確認して下さい。市場予測やSNDXの財務や市場ニュースもチェック。 Web9人のアナリストがsndxの1年先の価格予測を提供しており、その価格の最高値は—、最低値は—となっています。 アナリストの評価 過去3ヶ月間にSNDXの株価の評価を行ったアナリスト10名に拠ります。 ipb 2 fase